sb 202190 has been researched along with Leukemia, Basophilic, Acute in 1 studies
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase
Leukemia, Basophilic, Acute: A rare acute myeloid leukemia in which the primary differentiation is to BASOPHILS. It is characterized by an extreme increase of immature basophilic granulated cells in the bone marrow and blood. Mature basophils are usually sparse.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chaves-Dias, C | 1 |
| Hundley, TR | 1 |
| Gilfillan, AM | 1 |
| Kirshenbaum, AS | 1 |
| Cunha-Melo, JR | 1 |
| Metcalfe, DD | 1 |
| Beaven, MA | 1 |
1 other study available for sb 202190 and Leukemia, Basophilic, Acute
| Article | Year |
|---|---|
Induction of telomerase activity during development of human mast cells from peripheral blood CD34+ cells: comparisons with tumor mast-cell lines.
Topics: Acetamides; Androstadienes; Animals; Antigens, CD34; CD13 Antigens; Cell Cycle; Cell Differentiation | 2001 |